Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.0
4.5
Journals
Cancers
Special Issues
Advances in Multi-Omics of Pediatric, Adolescence and Young Adult Cancers
share announcement

Advances in Multi-Omics of Pediatric, Adolescence and Young Adult Cancers

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Methods and Technologies Development".

Deadline for manuscript submissions: closed (1 October 2024) | Viewed by 5430

Special Issue Editors

Dr. Somchai Chutipongtanate

E-Mail Website
Guest Editor
MILCH and Novel Therapeutics Lab, Division of Epidemiology, Department of Environmental and Public Health Sciences, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA
Interests: neuroblastoma; leukemia; tumor microenvironment; extracellular vesicle (EV); liquid biopsy; EV-based therapeutics; proteomics; glycoproteomics; multi-omics; connectivity mapping; drug discovery and repurposing; molecular epidemiology; systematic review and meta-analysis; precision medicine
Dr. Surasak Sangkhathat

E-Mail Website
Guest Editor
Translational Medicine Research Center, Departments of Surgery, Biomedical Science and Biomedical Engineering, Faculty of Medicine, Prince of Songkla University Hat Yai, Songkhla 90110, Thailand
Interests: pediatric solid tumors; colorectal cancer; minimal invasive surgery; molecular biology; multi-omics; precision medicine; surgical oncology
Dr. Dumnoensun Pruksakorn

E-Mail Website
Guest Editor
Center of Multidisciplinary Technologies for Advance Medicine (CMUTEAM), Department of Orthopedic Surgery, Faculty of Medicine Chiang Mai University, Chiang Mai, Thailand
Interests: osteosarcoma; liquid biopsy; precision medicine; proteomics; multi-omics; cancer predisposition syndrome; drug discovery and repurposing
Dr. Valli De Re

E-Mail Website
Guest Editor
Immunopathology and Oncological Biomarkers (IBO) Lab, Department of Translational Research and Advanced Diagnostics of Tumors (DRDT), Centro di Riferimento Oncologico (CRO), IRCCS, 33081 Aviano, Italy
Interests: biology of cancers of the gastrointestinal tract; Hodgkin's lymphoma, with a focus on infectious and autoimmune related factors
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Pediatric and adolescent and young adult (AYA) cancers are relatively uncommon but remain one of the leading causes of death in these age groups. Despite recent advances in multimodal cancer treatment, a significant proportion of pediatric and AYA cancer patients continue to experience poor outcomes. Omics technologies, including (but not limited to) genomics, transcriptomics, proteomics, and metabolomics, offer a comprehensive approach via which to better understand pediatric and AYA cancers. The integration of Omics data at multiple levels (multi-Omics) can provide a complete picture of the genetic and molecular alterations responsible for the poor outcomes observed in pediatric and AYA cancers, as well as identify novel therapeutic targets and discover molecular biomarkers that enable precise diagnosis and treatment.

This Special Issue aims to collect new evidence and perspectives from researchers who work at the interface between Omics technologies and pediatric and AYA cancers. Original research articles, short communications, and reviews (including systematic review and meta-analysis) are most welcome. Clinical case report/series that apply Omics in order to support clinical decision making regarding the diagnosis or treatment selection will also be considered for peer-review.

Research areas may include (but are not limited to) the following:

  • Omics as part of cancer biology, biomarker, and clinical studies in pediatric and AYA cancer
  • Updates in cancer predisposition genes and syndromes;
  • Cutting-edge Omics technologies applied to obtain new insights in pediatric and AYA cancers, e.g., single-cell Omics, spatial Omics, PTM (phospho-, ubiquitin-, glyco-) proteomics;
  • Extracellular vesicle (EV)-derived Omics in pediatric and AYA cancers;
  • Molecular epidemiology and exposomics in pediatric and AYA cancers;
  • Bioinformatic methods and tools, and new databases that facilitate Omics applications in pediatric and AYA cancers;
  • Cost analysis of Omics-based clinical investigations;
  • Validation study of Omics findings obtained from publicly available databases or previous publications using conventional methods and clinically compatible assays.

We look forward to receiving your contributions.

Dr. Somchai Chutipongtanate
Dr. Surasak Sangkhathat
Dr. Dumnoensun Pruksakorn
Dr. Valli De Re
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • AYA oncology
  • bioinformatics
  • childhood cancer
  • exposomics
  • genomics
  • integrative omics
  • metabolomics
  • precision medicine
  • proteomics
  • transcriptomics

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

14 pages, 2469 KiB  
Article
MERTK Is a Potential Therapeutic Target in Ewing Sarcoma
by Sherri K. Smart, Tsz Y. Yeung, M. Olivia Santos, Leon F. McSwain, Xiaodong Wang, Stephen V. Frye, H. Shelton Earp III, Deborah DeRyckere and Douglas K. Graham
Cancers 2024, 16(16), 2831; https://doi.org/10.3390/cancers16162831 - 12 Aug 2024
Viewed by 1206
Abstract
Outcomes are poor in patients with advanced or relapsed Ewing sarcoma (EWS) and current treatments have significant short- and long-term side effects. New, less toxic and more effective treatments are urgently needed. MER proto-oncogene tyrosine kinase (MERTK) promotes tumor cell survival, metastasis, and [...] Read more.
Outcomes are poor in patients with advanced or relapsed Ewing sarcoma (EWS) and current treatments have significant short- and long-term side effects. New, less toxic and more effective treatments are urgently needed. MER proto-oncogene tyrosine kinase (MERTK) promotes tumor cell survival, metastasis, and resistance to cytotoxic and targeted therapies in a variety of cancers. MERTK was ubiquitously expressed in five EWS cell lines and five patient samples. Moreover, data from CRISPR-based library screens indicated that EWS cell lines are particularly dependent on MERTK. Treatment with MRX-2843, a first-in-class, MERTK-selective tyrosine kinase inhibitor currently in clinical trials, decreased the phosphorylation of MERTK and downstream signaling in a dose-dependent manner in A673 and TC106 cells and provided potent anti-tumor activity against all five EWS cell lines, with IC50 values ranging from 178 to 297 nM. Inhibition of MERTK correlated with anti-tumor activity, suggesting MERTK inhibition as a therapeutic mechanism of MRX-2843. Combined treatment with MRX-2843 and BCL-2 inhibitors venetoclax or navitoclax provided enhanced therapeutic activity compared to single agents. These data highlight MERTK as a promising therapeutic target in EWS and provide rationale for the development of MRX-2843 for the treatment of EWS, especially in combination with BCL-2 inhibitors. Full article
(This article belongs to the Special Issue Advances in Multi-Omics of Pediatric, Adolescence and Young Adult Cancers)
►▼ Show Figures

Figure 1

Review

Jump to: Research

25 pages, 1772 KiB  
Review
Extracellular Vesicles for Childhood Cancer Liquid Biopsy
by Nilubon Singhto, Pongpak Pongphitcha, Natini Jinawath, Suradej Hongeng and Somchai Chutipongtanate
Cancers 2024, 16(9), 1681; https://doi.org/10.3390/cancers16091681 - 26 Apr 2024
Cited by 1 | Viewed by 1722
Abstract
Liquid biopsy involves the utilization of minimally invasive or noninvasive techniques to detect biomarkers in biofluids for disease diagnosis, monitoring, or guiding treatments. This approach is promising for the early diagnosis of childhood cancer, especially for brain tumors, where tissue biopsies are more [...] Read more.
Liquid biopsy involves the utilization of minimally invasive or noninvasive techniques to detect biomarkers in biofluids for disease diagnosis, monitoring, or guiding treatments. This approach is promising for the early diagnosis of childhood cancer, especially for brain tumors, where tissue biopsies are more challenging and cause late detection. Extracellular vesicles offer several characteristics that make them ideal resources for childhood cancer liquid biopsy. Extracellular vesicles are nanosized particles, primarily secreted by all cell types into body fluids such as blood and urine, and contain molecular cargos, i.e., lipids, proteins, and nucleic acids of original cells. Notably, the lipid bilayer-enclosed structure of extracellular vesicles protects their cargos from enzymatic degradation in the extracellular milieu. Proteins and nucleic acids of extracellular vesicles represent genetic alterations and molecular profiles of childhood cancer, thus serving as promising resources for precision medicine in cancer diagnosis, treatment monitoring, and prognosis prediction. This review evaluates the recent progress of extracellular vesicles as a liquid biopsy platform for various types of childhood cancer, discusses the mechanistic roles of molecular cargos in carcinogenesis and metastasis, and provides perspectives on extracellular vesicle-guided therapeutic intervention. Extracellular vesicle-based liquid biopsy for childhood cancer may ultimately contribute to improving patient outcomes. Full article
(This article belongs to the Special Issue Advances in Multi-Omics of Pediatric, Adolescence and Young Adult Cancers)
►▼ Show Figures

Figure 1

18 pages, 378 KiB  
Review
Early-Onset Gastrointestinal Malignancies: An Investigation into a Rising Concern
by Aayush Vishwanath, Shreyas Krishna, Albert P. Manudhane, Phil A. Hart and Somashekar G. Krishna
Cancers 2024, 16(8), 1553; https://doi.org/10.3390/cancers16081553 - 18 Apr 2024
Cited by 2 | Viewed by 2016
Abstract
There is growing recognition of early-onset gastrointestinal (GI) malignancies in young adults < 50 years of age. While much of the literature has emphasized colorectal cancer, these also include esophageal, gastric, liver, pancreatic, and biliary tract malignancies. Various factors, including lifestyle, hereditary, and [...] Read more.
There is growing recognition of early-onset gastrointestinal (GI) malignancies in young adults < 50 years of age. While much of the literature has emphasized colorectal cancer, these also include esophageal, gastric, liver, pancreatic, and biliary tract malignancies. Various factors, including lifestyle, hereditary, and environmental elements, have been proposed to explain the rising incidence of GI malignancies in the younger population. This review aims to provide an overview of the recent literature, including global trends and information regarding genetic and environmental risk factors. Full article
(This article belongs to the Special Issue Advances in Multi-Omics of Pediatric, Adolescence and Young Adult Cancers)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop